Publication date: Jun 25, 2025
The initial dosing of eight patients showed no significant adverse events, and the company expects interim data by the end of 2025. Their lead product, iSCIB1+ immunotherapy, is designed to treat multiple cancers, particularly melanoma, by leveraging the bodys immune system to identify and destroy tumors. However, recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a mixed trend with short-term bullish momentum, though overbought conditions warrant caution. Valuation remains unattractive, reflecting ongoing financial challenges. Check out TipRanks’ Best Online Brokers guide, and find the ideal broker for your trades.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | tumor |
| pathway | REACTOME | Immune System |
| pathway | KEGG | Melanoma |
| disease | MESH | Melanoma |